References

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975; 292(7):344-7. Google Scholar

  2. Marguerie C, Bunn CC, Beynon HL et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990; 77 (282):1019-38. PubMed | Google Scholar

  3. Brouwer R, Hengstman GJD, Egberts WV et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60(2):116-23. PubMed | Google Scholar

  4. Allali D, Seebach JD. Syndrome des antisynthétases: diagnostic et traitements. Rev Med Suisse. 2015; 11(469): 808-12. Google Scholar

  5. Marie I, Josse S, Decaux O et al. Comparison of longterm outcome between anti-jo1- and anti-pl7/pl12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012; 11(10):739-45. Google Scholar

  6. Hervier B, Devilliers H, Stanciu R et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-trna synthetase antibody specificity. Autoimmun Rev. 2012;12(2):210-7. PubMed | Google Scholar

  7. Marie I, Josse S, Hatron PYet al. Interstitial lung disease in anti-jo-1 patients with antisynthetase syndrome. Arthritis Care Res. 2013; 65(5):800-8. PubMed | Google Scholar

  8. Fujisawa T, Suda T, Nakamura Y et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005; 32(1):58-64. PubMed | Google Scholar

  9. Tillie-Leblond I, Wislez M, Valeyre D et al. Interstitial lung disease and anti-jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008; 63(1):53-9. PubMed | Google Scholar

  10. Hervier B, Meyer A, Dieval C et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J. 2013; 42(5):1271-82. PubMed | Google Scholar

  11. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus. 2000; 9(5):338-42. PubMed | Google Scholar

  12. Handa T, Nagai S, Kawabata D et al. Long-term clinical course of a patient with anti pl-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med. 2005; 44(4):319-25. PubMed | Google Scholar

  13. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009; 34(6):1219-63. PubMed | Google Scholar

  14. Cavagna L, Fusetti C, Montecucco C et al. Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome. J Rheumatol. 2010; 37(9): 1967. PubMed | Google Scholar

  15. Bachmeyer C, Tillie-Leblond I, Lacert A et al. "Mechanic's hands": a misleading cutaneous sign of the antisynthetase syndrome. Br J Dermatol. 2007; 156(1):192-4. PubMed | Google Scholar

  16. Hervier B, Lambert M, Hachulla E et al. Anti-synthetase syndrome positive for anti-isoleucyl-trna synthetase antibodies: an unusual case overlapping with systemic sclerosis and sjogren's syndrome. Rheumatology. 2011;50(6):1175-6. PubMed | Google Scholar

  17. Hervier B, Benveniste O. Phénotypes cliniques et pronostic du syndrome des antisynthétases. Rev Med Interne. 2014; 35(7):453-60. Google Scholar

  18. Ingegnoli F, Lubatti C, Ingegnoli A et al. Interstitial lung disease outcomes by high-resolution computed tomography (hrct) in anti-jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev. 2012; 11(5):335-40. PubMed | Google Scholar

  19. Tazelaar Hd, Viggiano Rw, Pickersgill J, Colby T. Interstitial lung disease in polymyositis and dermatopolymyositis: clinical features and prognosis as correlated with histologie findings. Am Rev Respir Dis. 1990; 141(3): 727-33.

  20. Bergoin C, Bure M. Le syndrome des anti-synthétases. Rev Mal Respir. 2002;19 (3): 371-374.

  21. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology. 2002; 41(1):7-13. Google Scholar

  22. Stanciu R, Guiguet M, Musset L et al. Antisynthetase syndrome with anti-jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol. 2012; 39(9):1835-9. PubMed | Google Scholar

  23. Sem M, Molberg O, Lund MB et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology. 2009; 48(8):968-71. PubMed | Google Scholar

  24. Marie I, Hatron PY, Cherin P et al. Functional outcome and prognostic factors in anti-jo1 patients with antisynthetase syndrome. Arthritis Res Ther. 2013; 15(5):R149. PubMed | Google Scholar

  25. Bozkirli DE, Kozanoglu I, Bozkirli E et al. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis. J Clin Apher. 2013; 28(6):422-5. PubMed | Google Scholar

  26. Dugar M, Cox S, Limaye V et al. Clinical heterogeneity and prognostic features of south australian patients with antisynthetase autoantibodies. Intern Med J. 2011; 41(9):674-9. Google Scholar